nodes	percent_of_prediction	percent_of_DWPC	metapath
Vilazodone—CYP3A4—type 2 diabetes mellitus	0.228	1	CbGaD
Vilazodone—CYP2C18—Tolbutamide—type 2 diabetes mellitus	0.158	0.295	CbGbCtD
Vilazodone—HTR1A—Bromocriptine—type 2 diabetes mellitus	0.0587	0.109	CbGbCtD
Vilazodone—DRD2—Bromocriptine—type 2 diabetes mellitus	0.0517	0.0962	CbGbCtD
Vilazodone—CYP2D6—Pioglitazone—type 2 diabetes mellitus	0.0272	0.0506	CbGbCtD
Vilazodone—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.0268	0.0499	CbGbCtD
Vilazodone—CYP2D6—Rosiglitazone—type 2 diabetes mellitus	0.0251	0.0467	CbGbCtD
Vilazodone—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.0239	0.0445	CbGbCtD
Vilazodone—CYP3A4—Glipizide—type 2 diabetes mellitus	0.0218	0.0407	CbGbCtD
Vilazodone—CYP2D6—Nateglinide—type 2 diabetes mellitus	0.0206	0.0383	CbGbCtD
Vilazodone—CYP2D6—Irbesartan—type 2 diabetes mellitus	0.0197	0.0367	CbGbCtD
Vilazodone—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.0191	0.0356	CbGbCtD
Vilazodone—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.0173	0.0322	CbGbCtD
Vilazodone—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.0131	0.0244	CbGbCtD
Vilazodone—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0125	0.0234	CbGbCtD
Vilazodone—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0125	0.0234	CbGbCtD
Vilazodone—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0119	0.0221	CbGbCtD
Vilazodone—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00884	0.0165	CbGbCtD
Vilazodone—CYP3A4—Losartan—type 2 diabetes mellitus	0.00808	0.0151	CbGbCtD
Vilazodone—Aripiprazole—ADRA2A—type 2 diabetes mellitus	0.000613	0.211	CrCbGaD
Vilazodone—Trazodone—ADRA2A—type 2 diabetes mellitus	0.00061	0.21	CrCbGaD
Vilazodone—Aripiprazole—HTR2C—type 2 diabetes mellitus	0.000564	0.194	CrCbGaD
Vilazodone—Trazodone—HTR2C—type 2 diabetes mellitus	0.000561	0.193	CrCbGaD
Vilazodone—Somnolence—Sitagliptin—type 2 diabetes mellitus	0.000343	0.00211	CcSEcCtD
Vilazodone—Diarrhoea—Repaglinide—type 2 diabetes mellitus	0.000343	0.00211	CcSEcCtD
Vilazodone—Fatigue—Pioglitazone—type 2 diabetes mellitus	0.000343	0.00211	CcSEcCtD
Vilazodone—Nervous system disorder—Bromocriptine—type 2 diabetes mellitus	0.000343	0.00211	CcSEcCtD
Vilazodone—Feeling abnormal—Glipizide—type 2 diabetes mellitus	0.000342	0.00211	CcSEcCtD
Vilazodone—Nervousness—Gliclazide—type 2 diabetes mellitus	0.000341	0.0021	CcSEcCtD
Vilazodone—Dyspepsia—Glimepiride—type 2 diabetes mellitus	0.000341	0.0021	CcSEcCtD
Vilazodone—Asthenia—Rosiglitazone—type 2 diabetes mellitus	0.00034	0.0021	CcSEcCtD
Vilazodone—Dyspepsia—Sitagliptin—type 2 diabetes mellitus	0.00034	0.00209	CcSEcCtD
Vilazodone—Skin disorder—Bromocriptine—type 2 diabetes mellitus	0.00034	0.00209	CcSEcCtD
Vilazodone—Convulsion—Glyburide—type 2 diabetes mellitus	0.000339	0.00209	CcSEcCtD
Vilazodone—Decreased appetite—Glimepiride—type 2 diabetes mellitus	0.000337	0.00207	CcSEcCtD
Vilazodone—Breast disorder—Ramipril—type 2 diabetes mellitus	0.000336	0.00207	CcSEcCtD
Vilazodone—Decreased appetite—Sitagliptin—type 2 diabetes mellitus	0.000336	0.00207	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Glimepiride—type 2 diabetes mellitus	0.000335	0.00206	CcSEcCtD
Vilazodone—Fatigue—Glimepiride—type 2 diabetes mellitus	0.000334	0.00206	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Sitagliptin—type 2 diabetes mellitus	0.000333	0.00205	CcSEcCtD
Vilazodone—Arthralgia—Glyburide—type 2 diabetes mellitus	0.000333	0.00205	CcSEcCtD
Vilazodone—Fatigue—Sitagliptin—type 2 diabetes mellitus	0.000333	0.00205	CcSEcCtD
Vilazodone—Connective tissue disorder—Metformin—type 2 diabetes mellitus	0.000332	0.00204	CcSEcCtD
Vilazodone—Tremor—Gliclazide—type 2 diabetes mellitus	0.000329	0.00203	CcSEcCtD
Vilazodone—Feeling abnormal—Pioglitazone—type 2 diabetes mellitus	0.000328	0.00202	CcSEcCtD
Vilazodone—Mental disorder—Valsartan—type 2 diabetes mellitus	0.000325	0.002	CcSEcCtD
Vilazodone—Diarrhoea—Rosiglitazone—type 2 diabetes mellitus	0.000325	0.002	CcSEcCtD
Vilazodone—Agitation—Gliclazide—type 2 diabetes mellitus	0.000323	0.00199	CcSEcCtD
Vilazodone—Malnutrition—Valsartan—type 2 diabetes mellitus	0.000323	0.00199	CcSEcCtD
Vilazodone—Mental disorder—Orlistat—type 2 diabetes mellitus	0.000321	0.00198	CcSEcCtD
Vilazodone—Feeling abnormal—Glimepiride—type 2 diabetes mellitus	0.000319	0.00197	CcSEcCtD
Vilazodone—Malnutrition—Orlistat—type 2 diabetes mellitus	0.000319	0.00197	CcSEcCtD
Vilazodone—Vomiting—Repaglinide—type 2 diabetes mellitus	0.000319	0.00196	CcSEcCtD
Vilazodone—Flatulence—Valsartan—type 2 diabetes mellitus	0.000318	0.00196	CcSEcCtD
Vilazodone—Feeling abnormal—Sitagliptin—type 2 diabetes mellitus	0.000318	0.00196	CcSEcCtD
Vilazodone—Dysgeusia—Valsartan—type 2 diabetes mellitus	0.000316	0.00195	CcSEcCtD
Vilazodone—Insomnia—Bromocriptine—type 2 diabetes mellitus	0.000316	0.00195	CcSEcCtD
Vilazodone—Eye disorder—Metformin—type 2 diabetes mellitus	0.000316	0.00194	CcSEcCtD
Vilazodone—Flatulence—Orlistat—type 2 diabetes mellitus	0.000315	0.00194	CcSEcCtD
Vilazodone—Paraesthesia—Bromocriptine—type 2 diabetes mellitus	0.000314	0.00193	CcSEcCtD
Vilazodone—Dizziness—Rosiglitazone—type 2 diabetes mellitus	0.000314	0.00193	CcSEcCtD
Vilazodone—Cardiac disorder—Metformin—type 2 diabetes mellitus	0.000314	0.00193	CcSEcCtD
Vilazodone—Nervous system disorder—Glyburide—type 2 diabetes mellitus	0.000313	0.00193	CcSEcCtD
Vilazodone—Connective tissue disorder—Irbesartan—type 2 diabetes mellitus	0.000313	0.00193	CcSEcCtD
Vilazodone—Dysgeusia—Orlistat—type 2 diabetes mellitus	0.000313	0.00192	CcSEcCtD
Vilazodone—Somnolence—Bromocriptine—type 2 diabetes mellitus	0.000311	0.00191	CcSEcCtD
Vilazodone—Palpitations—Gliclazide—type 2 diabetes mellitus	0.000311	0.00191	CcSEcCtD
Vilazodone—Hyperhidrosis—Glyburide—type 2 diabetes mellitus	0.000309	0.0019	CcSEcCtD
Vilazodone—Dyspepsia—Bromocriptine—type 2 diabetes mellitus	0.000308	0.00189	CcSEcCtD
Vilazodone—Convulsion—Gliclazide—type 2 diabetes mellitus	0.000305	0.00188	CcSEcCtD
Vilazodone—Vision blurred—Valsartan—type 2 diabetes mellitus	0.000304	0.00187	CcSEcCtD
Vilazodone—Decreased appetite—Bromocriptine—type 2 diabetes mellitus	0.000304	0.00187	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Bromocriptine—type 2 diabetes mellitus	0.000302	0.00186	CcSEcCtD
Vilazodone—Fatigue—Bromocriptine—type 2 diabetes mellitus	0.000301	0.00186	CcSEcCtD
Vilazodone—Vision blurred—Orlistat—type 2 diabetes mellitus	0.000301	0.00185	CcSEcCtD
Vilazodone—Arthralgia—Gliclazide—type 2 diabetes mellitus	0.000299	0.00184	CcSEcCtD
Vilazodone—Nausea—Repaglinide—type 2 diabetes mellitus	0.000298	0.00184	CcSEcCtD
Vilazodone—Asthenia—Glipizide—type 2 diabetes mellitus	0.000298	0.00183	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Gliclazide—type 2 diabetes mellitus	0.000297	0.00183	CcSEcCtD
Vilazodone—Erectile dysfunction—Ramipril—type 2 diabetes mellitus	0.000296	0.00182	CcSEcCtD
Vilazodone—Cardiac disorder—Irbesartan—type 2 diabetes mellitus	0.000296	0.00182	CcSEcCtD
Vilazodone—Malnutrition—Metformin—type 2 diabetes mellitus	0.000294	0.00181	CcSEcCtD
Vilazodone—Dry mouth—Gliclazide—type 2 diabetes mellitus	0.000293	0.0018	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Glyburide—type 2 diabetes mellitus	0.000291	0.00179	CcSEcCtD
Vilazodone—Flatulence—Metformin—type 2 diabetes mellitus	0.00029	0.00178	CcSEcCtD
Vilazodone—Dysgeusia—Metformin—type 2 diabetes mellitus	0.000288	0.00177	CcSEcCtD
Vilazodone—Feeling abnormal—Bromocriptine—type 2 diabetes mellitus	0.000288	0.00177	CcSEcCtD
Vilazodone—Paraesthesia—Glyburide—type 2 diabetes mellitus	0.000287	0.00177	CcSEcCtD
Vilazodone—Palpitations—Valsartan—type 2 diabetes mellitus	0.000285	0.00176	CcSEcCtD
Vilazodone—Asthenia—Pioglitazone—type 2 diabetes mellitus	0.000285	0.00176	CcSEcCtD
Vilazodone—Diarrhoea—Glipizide—type 2 diabetes mellitus	0.000284	0.00175	CcSEcCtD
Vilazodone—Palpitations—Orlistat—type 2 diabetes mellitus	0.000282	0.00174	CcSEcCtD
Vilazodone—Nausea—Rosiglitazone—type 2 diabetes mellitus	0.000282	0.00173	CcSEcCtD
Vilazodone—Aripiprazole—CYP3A4—type 2 diabetes mellitus	0.000282	0.0968	CrCbGaD
Vilazodone—Nervous system disorder—Gliclazide—type 2 diabetes mellitus	0.000281	0.00173	CcSEcCtD
Vilazodone—Dyspepsia—Glyburide—type 2 diabetes mellitus	0.000281	0.00173	CcSEcCtD
Vilazodone—Trazodone—CYP3A4—type 2 diabetes mellitus	0.00028	0.0964	CrCbGaD
Vilazodone—Skin disorder—Gliclazide—type 2 diabetes mellitus	0.000279	0.00172	CcSEcCtD
Vilazodone—Asthenia—Glimepiride—type 2 diabetes mellitus	0.000278	0.00171	CcSEcCtD
Vilazodone—Decreased appetite—Glyburide—type 2 diabetes mellitus	0.000278	0.00171	CcSEcCtD
Vilazodone—Malnutrition—Irbesartan—type 2 diabetes mellitus	0.000278	0.00171	CcSEcCtD
Vilazodone—Hyperhidrosis—Gliclazide—type 2 diabetes mellitus	0.000277	0.00171	CcSEcCtD
Vilazodone—Vision blurred—Metformin—type 2 diabetes mellitus	0.000277	0.00171	CcSEcCtD
Vilazodone—Asthenia—Sitagliptin—type 2 diabetes mellitus	0.000277	0.00171	CcSEcCtD
Vilazodone—Convulsion—Orlistat—type 2 diabetes mellitus	0.000277	0.0017	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Glyburide—type 2 diabetes mellitus	0.000276	0.0017	CcSEcCtD
Vilazodone—Tremor—Metformin—type 2 diabetes mellitus	0.000276	0.0017	CcSEcCtD
Vilazodone—Arthralgia—Valsartan—type 2 diabetes mellitus	0.000275	0.00169	CcSEcCtD
Vilazodone—Dizziness—Glipizide—type 2 diabetes mellitus	0.000275	0.00169	CcSEcCtD
Vilazodone—Flatulence—Irbesartan—type 2 diabetes mellitus	0.000274	0.00168	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Valsartan—type 2 diabetes mellitus	0.000273	0.00168	CcSEcCtD
Vilazodone—Diarrhoea—Pioglitazone—type 2 diabetes mellitus	0.000272	0.00168	CcSEcCtD
Vilazodone—Dysgeusia—Irbesartan—type 2 diabetes mellitus	0.000272	0.00167	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Orlistat—type 2 diabetes mellitus	0.00027	0.00166	CcSEcCtD
Vilazodone—Nervousness—Irbesartan—type 2 diabetes mellitus	0.00027	0.00166	CcSEcCtD
Vilazodone—Dry mouth—Valsartan—type 2 diabetes mellitus	0.000269	0.00166	CcSEcCtD
Vilazodone—Dry mouth—Orlistat—type 2 diabetes mellitus	0.000266	0.00164	CcSEcCtD
Vilazodone—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000265	0.00163	CcSEcCtD
Vilazodone—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000264	0.00163	CcSEcCtD
Vilazodone—Vomiting—Glipizide—type 2 diabetes mellitus	0.000264	0.00163	CcSEcCtD
Vilazodone—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000263	0.00162	CcSEcCtD
Vilazodone—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000263	0.00162	CcSEcCtD
Vilazodone—Vision blurred—Irbesartan—type 2 diabetes mellitus	0.000262	0.00161	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000261	0.00161	CcSEcCtD
Vilazodone—Tremor—Irbesartan—type 2 diabetes mellitus	0.00026	0.0016	CcSEcCtD
Vilazodone—Palpitations—Metformin—type 2 diabetes mellitus	0.00026	0.0016	CcSEcCtD
Vilazodone—Insomnia—Gliclazide—type 2 diabetes mellitus	0.00026	0.0016	CcSEcCtD
Vilazodone—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000259	0.00159	CcSEcCtD
Vilazodone—Paraesthesia—Gliclazide—type 2 diabetes mellitus	0.000258	0.00159	CcSEcCtD
Vilazodone—Flatulence—Losartan—type 2 diabetes mellitus	0.000257	0.00159	CcSEcCtD
Vilazodone—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000256	0.00158	CcSEcCtD
Vilazodone—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000256	0.00158	CcSEcCtD
Vilazodone—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000256	0.00158	CcSEcCtD
Vilazodone—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000255	0.00157	CcSEcCtD
Vilazodone—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000255	0.00157	CcSEcCtD
Vilazodone—Agitation—Irbesartan—type 2 diabetes mellitus	0.000255	0.00157	CcSEcCtD
Vilazodone—Somnolence—Gliclazide—type 2 diabetes mellitus	0.000255	0.00157	CcSEcCtD
Vilazodone—Nervousness—Losartan—type 2 diabetes mellitus	0.000254	0.00156	CcSEcCtD
Vilazodone—Skin disorder—Orlistat—type 2 diabetes mellitus	0.000253	0.00156	CcSEcCtD
Vilazodone—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.000253	0.00156	CcSEcCtD
Vilazodone—Dyspepsia—Gliclazide—type 2 diabetes mellitus	0.000253	0.00156	CcSEcCtD
Vilazodone—Hyperhidrosis—Orlistat—type 2 diabetes mellitus	0.000252	0.00155	CcSEcCtD
Vilazodone—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000251	0.00154	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000249	0.00153	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000248	0.00153	CcSEcCtD
Vilazodone—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000247	0.00152	CcSEcCtD
Vilazodone—Nausea—Glipizide—type 2 diabetes mellitus	0.000247	0.00152	CcSEcCtD
Vilazodone—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000246	0.00152	CcSEcCtD
Vilazodone—Vision blurred—Losartan—type 2 diabetes mellitus	0.000246	0.00152	CcSEcCtD
Vilazodone—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000246	0.00151	CcSEcCtD
Vilazodone—Tremor—Losartan—type 2 diabetes mellitus	0.000245	0.00151	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.00024	0.00148	CcSEcCtD
Vilazodone—Agitation—Losartan—type 2 diabetes mellitus	0.00024	0.00148	CcSEcCtD
Vilazodone—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000239	0.00147	CcSEcCtD
Vilazodone—Insomnia—Valsartan—type 2 diabetes mellitus	0.000238	0.00147	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000237	0.00146	CcSEcCtD
Vilazodone—Paraesthesia—Valsartan—type 2 diabetes mellitus	0.000237	0.00146	CcSEcCtD
Vilazodone—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000236	0.00146	CcSEcCtD
Vilazodone—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000236	0.00146	CcSEcCtD
Vilazodone—Insomnia—Orlistat—type 2 diabetes mellitus	0.000236	0.00145	CcSEcCtD
Vilazodone—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000235	0.00145	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.000235	0.00145	CcSEcCtD
Vilazodone—Somnolence—Valsartan—type 2 diabetes mellitus	0.000234	0.00144	CcSEcCtD
Vilazodone—Paraesthesia—Orlistat—type 2 diabetes mellitus	0.000234	0.00144	CcSEcCtD
Vilazodone—Skin disorder—Metformin—type 2 diabetes mellitus	0.000233	0.00144	CcSEcCtD
Vilazodone—Hyperhidrosis—Metformin—type 2 diabetes mellitus	0.000232	0.00143	CcSEcCtD
Vilazodone—Dyspepsia—Valsartan—type 2 diabetes mellitus	0.000232	0.00143	CcSEcCtD
Vilazodone—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000231	0.00142	CcSEcCtD
Vilazodone—Dry mouth—Irbesartan—type 2 diabetes mellitus	0.000231	0.00142	CcSEcCtD
Vilazodone—Palpitations—Losartan—type 2 diabetes mellitus	0.000231	0.00142	CcSEcCtD
Vilazodone—Nausea—Glimepiride—type 2 diabetes mellitus	0.00023	0.00142	CcSEcCtD
Vilazodone—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000229	0.00141	CcSEcCtD
Vilazodone—Dyspepsia—Orlistat—type 2 diabetes mellitus	0.000229	0.00141	CcSEcCtD
Vilazodone—Asthenia—Glyburide—type 2 diabetes mellitus	0.000229	0.00141	CcSEcCtD
Vilazodone—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000229	0.00141	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000228	0.0014	CcSEcCtD
Vilazodone—Fatigue—Valsartan—type 2 diabetes mellitus	0.000227	0.0014	CcSEcCtD
Vilazodone—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000226	0.00139	CcSEcCtD
Vilazodone—Mental disorder—Ramipril—type 2 diabetes mellitus	0.000225	0.00139	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000225	0.00138	CcSEcCtD
Vilazodone—Fatigue—Orlistat—type 2 diabetes mellitus	0.000225	0.00138	CcSEcCtD
Vilazodone—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000224	0.00138	CcSEcCtD
Vilazodone—Arthralgia—Losartan—type 2 diabetes mellitus	0.000222	0.00137	CcSEcCtD
Vilazodone—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000222	0.00137	CcSEcCtD
Vilazodone—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000222	0.00137	CcSEcCtD
Vilazodone—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.00022	0.00135	CcSEcCtD
Vilazodone—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000219	0.00135	CcSEcCtD
Vilazodone—Hyperhidrosis—Irbesartan—type 2 diabetes mellitus	0.000219	0.00135	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000219	0.00135	CcSEcCtD
Vilazodone—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000219	0.00135	CcSEcCtD
Vilazodone—Nervousness—Ramipril—type 2 diabetes mellitus	0.000218	0.00134	CcSEcCtD
Vilazodone—Dry mouth—Losartan—type 2 diabetes mellitus	0.000218	0.00134	CcSEcCtD
Vilazodone—Paraesthesia—Metformin—type 2 diabetes mellitus	0.000216	0.00133	CcSEcCtD
Vilazodone—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.000215	0.00132	CcSEcCtD
Vilazodone—Somnolence—Metformin—type 2 diabetes mellitus	0.000213	0.00131	CcSEcCtD
Vilazodone—Dyspepsia—Metformin—type 2 diabetes mellitus	0.000211	0.0013	CcSEcCtD
Vilazodone—Tremor—Ramipril—type 2 diabetes mellitus	0.00021	0.00129	CcSEcCtD
Vilazodone—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000209	0.00129	CcSEcCtD
Vilazodone—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000209	0.00128	CcSEcCtD
Vilazodone—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000208	0.00128	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000207	0.00128	CcSEcCtD
Vilazodone—Fatigue—Metformin—type 2 diabetes mellitus	0.000207	0.00127	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000206	0.00127	CcSEcCtD
Vilazodone—Hyperhidrosis—Losartan—type 2 diabetes mellitus	0.000206	0.00127	CcSEcCtD
Vilazodone—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000206	0.00127	CcSEcCtD
Vilazodone—Agitation—Ramipril—type 2 diabetes mellitus	0.000206	0.00127	CcSEcCtD
Vilazodone—Paraesthesia—Irbesartan—type 2 diabetes mellitus	0.000203	0.00125	CcSEcCtD
Vilazodone—Vomiting—Glyburide—type 2 diabetes mellitus	0.000203	0.00125	CcSEcCtD
Vilazodone—Somnolence—Irbesartan—type 2 diabetes mellitus	0.000201	0.00124	CcSEcCtD
Vilazodone—Dyspepsia—Irbesartan—type 2 diabetes mellitus	0.000199	0.00123	CcSEcCtD
Vilazodone—Palpitations—Ramipril—type 2 diabetes mellitus	0.000198	0.00122	CcSEcCtD
Vilazodone—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000198	0.00122	CcSEcCtD
Vilazodone—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000197	0.00121	CcSEcCtD
Vilazodone—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000196	0.00121	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.000196	0.0012	CcSEcCtD
Vilazodone—Fatigue—Irbesartan—type 2 diabetes mellitus	0.000195	0.0012	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	0.000194	0.0012	CcSEcCtD
Vilazodone—Convulsion—Ramipril—type 2 diabetes mellitus	0.000194	0.0012	CcSEcCtD
Vilazodone—Insomnia—Losartan—type 2 diabetes mellitus	0.000193	0.00119	CcSEcCtD
Vilazodone—Paraesthesia—Losartan—type 2 diabetes mellitus	0.000191	0.00118	CcSEcCtD
Vilazodone—Arthralgia—Ramipril—type 2 diabetes mellitus	0.000191	0.00117	CcSEcCtD
Vilazodone—Nausea—Glyburide—type 2 diabetes mellitus	0.00019	0.00117	CcSEcCtD
Vilazodone—Dizziness—Gliclazide—type 2 diabetes mellitus	0.00019	0.00117	CcSEcCtD
Vilazodone—Somnolence—Losartan—type 2 diabetes mellitus	0.00019	0.00117	CcSEcCtD
Vilazodone—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	0.000189	0.00117	CcSEcCtD
Vilazodone—Asthenia—Valsartan—type 2 diabetes mellitus	0.000189	0.00116	CcSEcCtD
Vilazodone—Dyspepsia—Losartan—type 2 diabetes mellitus	0.000188	0.00116	CcSEcCtD
Vilazodone—Asthenia—Orlistat—type 2 diabetes mellitus	0.000187	0.00115	CcSEcCtD
Vilazodone—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	0.000187	0.00115	CcSEcCtD
Vilazodone—Dry mouth—Ramipril—type 2 diabetes mellitus	0.000187	0.00115	CcSEcCtD
Vilazodone—Decreased appetite—Losartan—type 2 diabetes mellitus	0.000185	0.00114	CcSEcCtD
Vilazodone—Fatigue—Losartan—type 2 diabetes mellitus	0.000184	0.00113	CcSEcCtD
Vilazodone—Vomiting—Gliclazide—type 2 diabetes mellitus	0.000182	0.00112	CcSEcCtD
Vilazodone—Diarrhoea—Valsartan—type 2 diabetes mellitus	0.00018	0.00111	CcSEcCtD
Vilazodone—Nervous system disorder—Ramipril—type 2 diabetes mellitus	0.000179	0.0011	CcSEcCtD
Vilazodone—Diarrhoea—Orlistat—type 2 diabetes mellitus	0.000178	0.0011	CcSEcCtD
Vilazodone—Skin disorder—Ramipril—type 2 diabetes mellitus	0.000178	0.00109	CcSEcCtD
Vilazodone—Hyperhidrosis—Ramipril—type 2 diabetes mellitus	0.000177	0.00109	CcSEcCtD
Vilazodone—Feeling abnormal—Losartan—type 2 diabetes mellitus	0.000176	0.00108	CcSEcCtD
Vilazodone—Dizziness—Valsartan—type 2 diabetes mellitus	0.000174	0.00107	CcSEcCtD
Vilazodone—Dizziness—Orlistat—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Vilazodone—Asthenia—Metformin—type 2 diabetes mellitus	0.000172	0.00106	CcSEcCtD
Vilazodone—Nausea—Gliclazide—type 2 diabetes mellitus	0.00017	0.00105	CcSEcCtD
Vilazodone—Vomiting—Valsartan—type 2 diabetes mellitus	0.000168	0.00103	CcSEcCtD
Vilazodone—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	0.000167	0.00103	CcSEcCtD
Vilazodone—Vomiting—Orlistat—type 2 diabetes mellitus	0.000166	0.00102	CcSEcCtD
Vilazodone—Insomnia—Ramipril—type 2 diabetes mellitus	0.000165	0.00102	CcSEcCtD
Vilazodone—Diarrhoea—Metformin—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Vilazodone—Paraesthesia—Ramipril—type 2 diabetes mellitus	0.000164	0.00101	CcSEcCtD
Vilazodone—Asthenia—Irbesartan—type 2 diabetes mellitus	0.000163	0.001	CcSEcCtD
Vilazodone—Somnolence—Ramipril—type 2 diabetes mellitus	0.000163	0.001	CcSEcCtD
Vilazodone—Dyspepsia—Ramipril—type 2 diabetes mellitus	0.000161	0.000991	CcSEcCtD
Vilazodone—Decreased appetite—Ramipril—type 2 diabetes mellitus	0.000159	0.000979	CcSEcCtD
Vilazodone—Dizziness—Metformin—type 2 diabetes mellitus	0.000159	0.000977	CcSEcCtD
Vilazodone—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	0.000158	0.000972	CcSEcCtD
Vilazodone—Fatigue—Ramipril—type 2 diabetes mellitus	0.000158	0.000971	CcSEcCtD
Vilazodone—Nausea—Valsartan—type 2 diabetes mellitus	0.000157	0.000964	CcSEcCtD
Vilazodone—Diarrhoea—Irbesartan—type 2 diabetes mellitus	0.000155	0.000954	CcSEcCtD
Vilazodone—Nausea—Orlistat—type 2 diabetes mellitus	0.000155	0.000953	CcSEcCtD
Vilazodone—Asthenia—Losartan—type 2 diabetes mellitus	0.000153	0.000942	CcSEcCtD
Vilazodone—Vomiting—Metformin—type 2 diabetes mellitus	0.000153	0.00094	CcSEcCtD
Vilazodone—Feeling abnormal—Ramipril—type 2 diabetes mellitus	0.000151	0.000928	CcSEcCtD
Vilazodone—Dizziness—Irbesartan—type 2 diabetes mellitus	0.00015	0.000922	CcSEcCtD
Vilazodone—Diarrhoea—Losartan—type 2 diabetes mellitus	0.000146	0.000898	CcSEcCtD
Vilazodone—Vomiting—Irbesartan—type 2 diabetes mellitus	0.000144	0.000887	CcSEcCtD
Vilazodone—Nausea—Metformin—type 2 diabetes mellitus	0.000143	0.000878	CcSEcCtD
Vilazodone—Dizziness—Losartan—type 2 diabetes mellitus	0.000141	0.000868	CcSEcCtD
Vilazodone—Vomiting—Losartan—type 2 diabetes mellitus	0.000136	0.000835	CcSEcCtD
Vilazodone—Nausea—Irbesartan—type 2 diabetes mellitus	0.000135	0.000829	CcSEcCtD
Vilazodone—Asthenia—Ramipril—type 2 diabetes mellitus	0.000131	0.000808	CcSEcCtD
Vilazodone—Nausea—Losartan—type 2 diabetes mellitus	0.000127	0.00078	CcSEcCtD
Vilazodone—Diarrhoea—Ramipril—type 2 diabetes mellitus	0.000125	0.00077	CcSEcCtD
Vilazodone—Dizziness—Ramipril—type 2 diabetes mellitus	0.000121	0.000744	CcSEcCtD
Vilazodone—Vomiting—Ramipril—type 2 diabetes mellitus	0.000116	0.000716	CcSEcCtD
Vilazodone—Nausea—Ramipril—type 2 diabetes mellitus	0.000109	0.000669	CcSEcCtD
Vilazodone—DRD2—GPCR downstream signaling—PRKCB—type 2 diabetes mellitus	1.23e-05	0.000176	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PSMD6—type 2 diabetes mellitus	1.23e-05	0.000176	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HTR2C—type 2 diabetes mellitus	1.23e-05	0.000176	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.23e-05	0.000176	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—INS—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—G6PC—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ND1—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HBA2—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPP1R3C—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ENPP1—type 2 diabetes mellitus	1.22e-05	0.000175	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GCG—type 2 diabetes mellitus	1.21e-05	0.000174	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.21e-05	0.000174	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AGT—type 2 diabetes mellitus	1.21e-05	0.000173	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LPA—type 2 diabetes mellitus	1.2e-05	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCKR—type 2 diabetes mellitus	1.2e-05	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—KCNJ11—type 2 diabetes mellitus	1.2e-05	0.000172	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HSD3B2—type 2 diabetes mellitus	1.2e-05	0.000172	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EDNRA—type 2 diabetes mellitus	1.19e-05	0.000171	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.19e-05	0.000171	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CALM1—type 2 diabetes mellitus	1.19e-05	0.00017	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CYBA—type 2 diabetes mellitus	1.19e-05	0.00017	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.19e-05	0.00017	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCGR—type 2 diabetes mellitus	1.18e-05	0.000169	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADRA2A—type 2 diabetes mellitus	1.17e-05	0.000167	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GHRL—type 2 diabetes mellitus	1.16e-05	0.000167	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PLAT—type 2 diabetes mellitus	1.16e-05	0.000167	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALDOB—type 2 diabetes mellitus	1.15e-05	0.000165	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CALCA—type 2 diabetes mellitus	1.15e-05	0.000165	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—CCL2—type 2 diabetes mellitus	1.13e-05	0.000162	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—ALB—type 2 diabetes mellitus	1.12e-05	0.00016	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PRKCB—type 2 diabetes mellitus	1.12e-05	0.00016	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYTB—type 2 diabetes mellitus	1.11e-05	0.00016	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—OXCT1—type 2 diabetes mellitus	1.11e-05	0.00016	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT2—type 2 diabetes mellitus	1.11e-05	0.00016	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	1.11e-05	0.000159	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SRD5A1—type 2 diabetes mellitus	1.09e-05	0.000156	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TCF7L2—type 2 diabetes mellitus	1.08e-05	0.000155	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT2—type 2 diabetes mellitus	1.08e-05	0.000154	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GLP1R—type 2 diabetes mellitus	1.07e-05	0.000153	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—NOS3—type 2 diabetes mellitus	1.07e-05	0.000153	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PIK3R1—type 2 diabetes mellitus	1.07e-05	0.000153	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GCG—type 2 diabetes mellitus	1.06e-05	0.000152	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PTPN1—type 2 diabetes mellitus	1.06e-05	0.000152	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	1.05e-05	0.000151	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RASGRP1—type 2 diabetes mellitus	1.05e-05	0.00015	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—GNB3—type 2 diabetes mellitus	1.04e-05	0.00015	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOTCH2—type 2 diabetes mellitus	1.04e-05	0.000149	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—STAR—type 2 diabetes mellitus	1.04e-05	0.000148	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSD17B3—type 2 diabetes mellitus	1.04e-05	0.000148	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ACACA—type 2 diabetes mellitus	1.04e-05	0.000148	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AVP—type 2 diabetes mellitus	1.03e-05	0.000148	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP3—type 2 diabetes mellitus	1.03e-05	0.000148	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF2—type 2 diabetes mellitus	1.03e-05	0.000147	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	1.02e-05	0.000146	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	1.01e-05	0.000145	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A2—type 2 diabetes mellitus	1e-05	0.000143	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOB—type 2 diabetes mellitus	9.96e-06	0.000143	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—CCL2—type 2 diabetes mellitus	9.96e-06	0.000143	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ABCC8—type 2 diabetes mellitus	9.94e-06	0.000142	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CBS—type 2 diabetes mellitus	9.94e-06	0.000142	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1R—type 2 diabetes mellitus	9.92e-06	0.000142	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EDN1—type 2 diabetes mellitus	9.8e-06	0.00014	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CPT1A—type 2 diabetes mellitus	9.79e-06	0.00014	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTR—type 2 diabetes mellitus	9.79e-06	0.00014	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—PTGS2—type 2 diabetes mellitus	9.79e-06	0.00014	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT2—type 2 diabetes mellitus	9.78e-06	0.00014	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—PIK3R1—type 2 diabetes mellitus	9.77e-06	0.00014	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NAMPT—type 2 diabetes mellitus	9.6e-06	0.000138	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC5A2—type 2 diabetes mellitus	9.56e-06	0.000137	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—COX2—type 2 diabetes mellitus	9.56e-06	0.000137	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HBA1—type 2 diabetes mellitus	9.54e-06	0.000137	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LIPC—type 2 diabetes mellitus	9.54e-06	0.000137	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCK—type 2 diabetes mellitus	9.54e-06	0.000137	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LPL—type 2 diabetes mellitus	9.51e-06	0.000136	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP11A1—type 2 diabetes mellitus	9.48e-06	0.000136	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NCOA6—type 2 diabetes mellitus	9.4e-06	0.000135	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC9A1—type 2 diabetes mellitus	9.31e-06	0.000133	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—ADCY5—type 2 diabetes mellitus	9.31e-06	0.000133	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFBR2—type 2 diabetes mellitus	9.25e-06	0.000133	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSD11B1—type 2 diabetes mellitus	9.24e-06	0.000132	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—UCP2—type 2 diabetes mellitus	9.24e-06	0.000132	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—UCP3—type 2 diabetes mellitus	9.24e-06	0.000132	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CETP—type 2 diabetes mellitus	9.21e-06	0.000132	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—GNB3—type 2 diabetes mellitus	9.17e-06	0.000131	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AVP—type 2 diabetes mellitus	9.05e-06	0.00013	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP3—type 2 diabetes mellitus	9.05e-06	0.00013	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF2—type 2 diabetes mellitus	9.01e-06	0.000129	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CDKN2B—type 2 diabetes mellitus	8.97e-06	0.000128	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	8.92e-06	0.000128	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—PIK3R1—type 2 diabetes mellitus	8.87e-06	0.000127	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCR5—type 2 diabetes mellitus	8.76e-06	0.000126	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOB—type 2 diabetes mellitus	8.74e-06	0.000125	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1R—type 2 diabetes mellitus	8.71e-06	0.000125	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PCK1—type 2 diabetes mellitus	8.68e-06	0.000124	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EDN1—type 2 diabetes mellitus	8.6e-06	0.000123	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—C3—type 2 diabetes mellitus	8.56e-06	0.000123	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PSMD6—type 2 diabetes mellitus	8.56e-06	0.000123	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SNAP25—type 2 diabetes mellitus	8.56e-06	0.000123	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SREBF1—type 2 diabetes mellitus	8.56e-06	0.000123	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CTGF—type 2 diabetes mellitus	8.4e-06	0.00012	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LPL—type 2 diabetes mellitus	8.35e-06	0.00012	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMGCR—type 2 diabetes mellitus	8.33e-06	0.000119	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—ADCY5—type 2 diabetes mellitus	8.17e-06	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—HIF1A—type 2 diabetes mellitus	8.16e-06	0.000117	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADRA2A—type 2 diabetes mellitus	8.15e-06	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IRS2—type 2 diabetes mellitus	8.14e-06	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AGT—type 2 diabetes mellitus	8.13e-06	0.000117	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HK1—type 2 diabetes mellitus	8.13e-06	0.000117	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CALM1—type 2 diabetes mellitus	8e-06	0.000115	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOE—type 2 diabetes mellitus	7.97e-06	0.000114	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—LEP—type 2 diabetes mellitus	7.97e-06	0.000114	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—APOA1—type 2 diabetes mellitus	7.88e-06	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—KCNJ11—type 2 diabetes mellitus	7.85e-06	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LPA—type 2 diabetes mellitus	7.85e-06	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HSD3B2—type 2 diabetes mellitus	7.85e-06	0.000113	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCKR—type 2 diabetes mellitus	7.85e-06	0.000113	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PPP2CA—type 2 diabetes mellitus	7.83e-06	0.000112	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP2E1—type 2 diabetes mellitus	7.83e-06	0.000112	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP1A2—type 2 diabetes mellitus	7.74e-06	0.000111	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A1—type 2 diabetes mellitus	7.74e-06	0.000111	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCR5—type 2 diabetes mellitus	7.69e-06	0.00011	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CYP3A4—type 2 diabetes mellitus	7.55e-06	0.000108	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALDOB—type 2 diabetes mellitus	7.53e-06	0.000108	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—C3—type 2 diabetes mellitus	7.52e-06	0.000108	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PRKCB—type 2 diabetes mellitus	7.52e-06	0.000108	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GCG—type 2 diabetes mellitus	7.42e-06	0.000106	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—SLC2A4—type 2 diabetes mellitus	7.42e-06	0.000106	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—HIF1A—type 2 diabetes mellitus	7.17e-06	0.000103	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IRS2—type 2 diabetes mellitus	7.15e-06	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AGT—type 2 diabetes mellitus	7.14e-06	0.000102	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IRS1—type 2 diabetes mellitus	7.11e-06	0.000102	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CALM1—type 2 diabetes mellitus	7.02e-06	0.000101	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	7e-06	0.0001	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—LEP—type 2 diabetes mellitus	7e-06	0.0001	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOE—type 2 diabetes mellitus	7e-06	0.0001	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—APOA1—type 2 diabetes mellitus	6.92e-06	9.91e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—INS—type 2 diabetes mellitus	6.81e-06	9.76e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.7e-06	9.6e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.6e-06	9.46e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.59e-06	9.44e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.58e-06	9.43e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—EGFR—type 2 diabetes mellitus	6.55e-06	9.39e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.54e-06	9.36e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	6.4e-06	9.17e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	6.4e-06	9.17e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GNB3—type 2 diabetes mellitus	6.4e-06	9.17e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.4e-06	9.17e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—HMOX1—type 2 diabetes mellitus	6.37e-06	9.12e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CAT—type 2 diabetes mellitus	6.28e-06	9e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	6.28e-06	9e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.25e-06	8.96e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.24e-06	8.94e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	6.24e-06	8.94e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	6.24e-06	8.94e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	6.24e-06	8.94e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	6.2e-06	8.88e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOB—type 2 diabetes mellitus	6.1e-06	8.74e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	6.09e-06	8.73e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	6.02e-06	8.63e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—INS—type 2 diabetes mellitus	5.98e-06	8.57e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.97e-06	8.56e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.97e-06	8.56e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GSTM1—type 2 diabetes mellitus	5.93e-06	8.5e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.88e-06	8.43e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—LPL—type 2 diabetes mellitus	5.82e-06	8.34e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.78e-06	8.28e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.78e-06	8.28e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—EGFR—type 2 diabetes mellitus	5.75e-06	8.24e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ADCY5—type 2 diabetes mellitus	5.7e-06	8.17e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—GPX1—type 2 diabetes mellitus	5.68e-06	8.14e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—RELA—type 2 diabetes mellitus	5.62e-06	8.05e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.6e-06	8.02e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.6e-06	8.02e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.6e-06	8.02e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CD36—type 2 diabetes mellitus	5.53e-06	7.93e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.49e-06	7.87e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.49e-06	7.87e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPP2CA—type 2 diabetes mellitus	5.46e-06	7.83e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.44e-06	7.8e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	5.33e-06	7.63e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—MTHFR—type 2 diabetes mellitus	5.24e-06	7.51e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.24e-06	7.51e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.24e-06	7.51e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARA—type 2 diabetes mellitus	5.14e-06	7.37e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	5.12e-06	7.33e-05	CbGpPWpGaD
Vilazodone—HTR1A—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	5.12e-06	7.33e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.07e-06	7.26e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	5.06e-06	7.25e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	5.06e-06	7.25e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.04e-06	7.22e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AGT—type 2 diabetes mellitus	4.98e-06	7.14e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—RELA—type 2 diabetes mellitus	4.93e-06	7.07e-05	CbGpPWpGaD
Vilazodone—CYP2C18—Metabolism—AKT1—type 2 diabetes mellitus	4.92e-06	7.05e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—CALM1—type 2 diabetes mellitus	4.9e-06	7.02e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOE—type 2 diabetes mellitus	4.88e-06	6.99e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.85e-06	6.95e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.85e-06	6.95e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—APOA1—type 2 diabetes mellitus	4.83e-06	6.91e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.79e-06	6.86e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.74e-06	6.79e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.65e-06	6.66e-05	CbGpPWpGaD
Vilazodone—DRD2—GPCR downstream signaling—AKT1—type 2 diabetes mellitus	4.49e-06	6.44e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.45e-06	6.38e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—IL6—type 2 diabetes mellitus	4.42e-06	6.34e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—SRC—type 2 diabetes mellitus	4.42e-06	6.33e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.3e-06	6.16e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PPARG—type 2 diabetes mellitus	4.25e-06	6.09e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.21e-06	6.03e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	4.18e-06	5.99e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	4.18e-06	5.99e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—INS—type 2 diabetes mellitus	4.17e-06	5.98e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	4.16e-06	5.96e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.16e-06	5.96e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	4.11e-06	5.89e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.08e-06	5.84e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.99e-06	5.71e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.95e-06	5.66e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.88e-06	5.56e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—SRC—type 2 diabetes mellitus	3.88e-06	5.56e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.87e-06	5.55e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—ALB—type 2 diabetes mellitus	3.82e-06	5.48e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.81e-06	5.46e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.78e-06	5.41e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.73e-06	5.34e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.71e-06	5.32e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—NOS3—type 2 diabetes mellitus	3.66e-06	5.24e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PIK3R1—type 2 diabetes mellitus	3.66e-06	5.24e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.62e-06	5.18e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.57e-06	5.12e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.47e-06	4.97e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.43e-06	4.91e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.4e-06	4.87e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.36e-06	4.82e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—PTGS2—type 2 diabetes mellitus	3.34e-06	4.79e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.26e-06	4.67e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	3.2e-06	4.59e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	3.19e-06	4.57e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	3.15e-06	4.52e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—IL6—type 2 diabetes mellitus	2.98e-06	4.26e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.78e-06	3.98e-05	CbGpPWpGaD
Vilazodone—HTR1A—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.74e-06	3.93e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.73e-06	3.91e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—IL6—type 2 diabetes mellitus	2.61e-06	3.74e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.5e-06	3.58e-05	CbGpPWpGaD
Vilazodone—DRD2—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.41e-06	3.45e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.39e-06	3.43e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.39e-06	3.43e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.19e-06	3.13e-05	CbGpPWpGaD
Vilazodone—CYP2D6—Metabolism—AKT1—type 2 diabetes mellitus	1.68e-06	2.41e-05	CbGpPWpGaD
Vilazodone—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.1e-06	1.57e-05	CbGpPWpGaD
